US academic fleet cuts operations as budget bites
Budget freezes and high fuel costs will force one vessel in the US academic oceanographic fleet -probably from an East Coast institution -to remain docked throughout 2009. Two other members of the fleet's 23 ships will run on only partial schedules.
At their annual meeting in Arlington, Virginia, last week, council members of the University-National Oceanographic Laboratories System (UNOLS) said the cutbacks were necessary to save money. Despite sidelining ships, UNOLS still faces one of its largest ever deficits, of $19 million, in its $100-million budget to fund next year's fleet.
Final plans to select the ships and strategies to cover the deficit will be made by the end of October.
Italy to create biomedicalresearch funding system
The Italian government has pledged to create a formal system for the competitive distribution of funds for biomedical research, which will conform to international standards of peer review and transparency.
The statement of intent has partially mollified biologists, some of whom last year protested the murky allocation of research funds by the ISS, Italy's health-research institute in Rome. Stem-cell researchers were particularly angry about how funds earmarked for their field were distributed (see Nature 450, 320; 2007).
The health ministry, which made the announcement on 1 October, has not yet indicated when the system would come into effect.
Eli Lilly wins race to take control of ImClone
Pharmaceuticals giant Eli Lilly, of Indianapolis, Indiana, seems to have beaten its rival Bristol-Myers Squibb in the competition for ImClone, a biotechnology firm based in New York. On 6 October, Eli Lilly and ImClone announced that they had agreed to a US$6.5-billion merger.
Bristol-Myers Squibb, also of New York, owns 17% of ImClone and has an agreement to market its blockbuster anticancer drug Erbitux (cetuximab), a monoclonal antibody. In July Bristol-Myers Squibb failed in a bid to buy the biotech company, offering $60 a share, when ImClone's shares were trading at around $40-45. A follow-up offer of $62 a share was also turned down. The Eli Lilly deal values the company at $70 a share.
Bristol-Myers Squibb is unlikely to bid again, so agreement with Eli Lilly is being seen as the endgame of the protracted wrangling over the company, Erbitux and promising follow-up monoclonal antibodies.
United States agrees to sell nuclear fuel to India
India can buy nuclear fuel and technologies from the United States, now that the US Senate has approved the '123 deal' .
The vote, along with earlier waivers from the Nuclear Suppliers Group and the International Atomic Energy Agency, makes India the only country with nuclear weapons that can legally engage in nuclear commerce without first having signed the Nuclear Non-Proliferation Treaty.
US secretary of state Condoleezza Rice was to have sealed the deal on a visit to New Delhi last weekend. As Nature went to press, President George W. Bush was expected to sign the deal on 8 October.
Some of the US research fleet may be suspended.
SOEST/UNIV. HAWAII C. FURLONG/GETTY IMAGES Wall Street bill boosts renewable energies
The US Congress last week extended some $17 billion in tax incentives for wind, solar and other renewable energies as part of the rescue package for Wall Street banks.
The tax credits had been set to expire at the end of this year, and legislation extending them had languished for months over disputes on how to pay for them (see Nature 455, 572-573; 2008) . A resolution seemed unlikely until Senate leaders wrapped it into the bailout package.
The legislation extends for one year a tax credit for producing wind power that is currently valued at 2 cents per kilowatt hour. The solar industry came out particularly well with an eight-year extension of its 30% investment tax credit.
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